PDMR
|
Ordinary Shares acquired under the AZDBP
|
Pascal
Soriot
|
15,755
|
Marc
Dunoyer
|
4,838
|
Media
Relations
|
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
Jennifer
Hursit
|
UK/Global
|
+44
203 749 5762
|
Christina M
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Christer
Gruvris
|
BioPharma
- Cardiovascular; Metabolism
|
+44 203
749 5711
|
Nick
Stone
|
BioPharma
- Respiratory; Renal
|
+44 203
749 5716
|
Josie
Afolabi
|
Other
|
+44 203
749 5631
|
Craig
Marks
|
Finance;
Fixed Income
|
+44
7881 615 764
|
Jennifer
Kretzmann
|
Retail
Investors; Corporate Access
|
+44 203
749 5824
|
US
toll-free
|
|
+1 866
381 72 77
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
a)
|
Name
|
Pascal
Soriot
|
|
2
|
Reason for the notification
|
||
a)
|
Position/status
|
Chief
Executive Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Deferred Bonus Plan, for nil consideration.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
15,755
|
||
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
29
March 2019
|
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
a)
|
Name
|
Marc
Dunoyer
|
|
2
|
Reason for the notification
|
||
a)
|
Position/status
|
Chief
Financial Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Deferred Bonus Plan, for nil consideration.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
4,838
|
||
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
29
March 2019
|
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|